These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2977219)

  • 21. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
    Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
    Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
    Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
    [No Abstract]   [Full Text] [Related]  

  • 23. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
    Furr BJ; Hutchinson FG
    Prog Clin Biol Res; 1985; 185A():143-53. PubMed ID: 3162174
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK; Jacobi GH
    Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residual androgen depending in hormone-resistant prostate cancer.
    Fosså SD
    Acta Oncol; 1997; 36(1):81-2. PubMed ID: 9090973
    [No Abstract]   [Full Text] [Related]  

  • 27. Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.
    Johansen TE; Ogreid P; Kjellevold K; Blom P
    Br J Urol; 1990 Apr; 65(4):376-8. PubMed ID: 2140282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
    Nicholson RI; Walker KJ
    Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine treatment of prostate cancer.
    Turkes AO; Griffiths K
    Prog Med Chem; 1989; 26():299-321. PubMed ID: 2532376
    [No Abstract]   [Full Text] [Related]  

  • 30. Preliminary report on a phase II multicentric study on depot LH-RH analogue in advanced prostatic cancer.
    Bono AV; Pozzi E; Bianco A; Morelli A; Bolgan A; Albano D; Frugoni A; Usai E
    Prog Clin Biol Res; 1987; 243A():251-3. PubMed ID: 2958856
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
    Allen JM; Williams G; O'Shea JP; Smith C; Yeo T; Kerle D; Bloom SR
    Urol Res; 1984; 12(5):249-51. PubMed ID: 6240150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 34. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 35. Antithrombin III concentration, thrombosis, and treatment with luteinising hormone releasing hormone agonist in prostatic carcinoma.
    Varenhorst E; Svensson M; Hjertberg H; Malmqvist E
    Br Med J (Clin Res Ed); 1986 Apr; 292(6525):935-6. PubMed ID: 2938662
    [No Abstract]   [Full Text] [Related]  

  • 36. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 37. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
    Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
    Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
    [No Abstract]   [Full Text] [Related]  

  • 38. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
    Emtage LA; Trethowan C; Hilton C; Kelly K; Blackledge GR
    Am J Clin Oncol; 1988; 11 Suppl 2():S173-5. PubMed ID: 2977273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of a LHRH agonist (Zoladex) in hormonotherapy of advanced cancers of the prostate. Apropos of 22 patients].
    Bourgne N; Audhuy B; Kohser F; Levin G
    Rev Med Interne; 1987; 8(3):325-30. PubMed ID: 2956658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
    Kaisary AV; Tyrrell CJ; Peeling WB; Griffiths K
    Br J Urol; 1991 May; 67(5):502-8. PubMed ID: 1828183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.